As announced in the morning, the board of directors of the company was pleased to announce that ISM6331, a potentially best-in-class broad-spectrum TEAD inhibitor independently developed by the company and empowered by artificial intelligence technology, has been granted fast-track status by the US Food and Drug Administration. The indications are adult patients with unresectable malignant pleural mesothelioma — the condition of such patients is still progressing after treatment with anti-PD-1 antibody monotherapy or a combination anti-CTLA-4 antibody or platinum chemotherapy regimen.
Zhitongcaijing · 3d ago
Share
Listen to the news
As announced in the morning, the board of directors of the company was pleased to announce that ISM6331, a potentially best-in-class broad-spectrum TEAD inhibitor independently developed by the company and empowered by artificial intelligence technology, has been granted fast-track status by the US Food and Drug Administration. The indications are adult patients with unresectable malignant pleural mesothelioma — the condition of such patients is still progressing after treatment with anti-PD-1 antibody monotherapy or a combination anti-CTLA-4 antibody or platinum chemotherapy regimen.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending